FDA accepts supplemental Biologics License Application for rilonacept for treatment of recurrent pericarditis

Rilonacept is a weekly, subcutaneously-injected, recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signalling. The regulatory submission was based on positive data from Phase 3 RHAPSODY trial.

Source:

Biospace Inc.